Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
3.03
-0.05 (-1.62%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.09
52 week 2.82 - 5.90
Open 3.07
Vol / Avg. 63,267.00/68,984.00
Mkt cap 60.47M
P/E     -
Div/yield     -
EPS -2.27
Shares 19.96M
Beta 1.75
Inst. own 22%
Nov 10, 2014
Q3 2014 Celsion Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 9, 2014
Celsion Corp at Rodman & Renshaw Global Investment Conference
Aug 7, 2014
Q2 2014 Celsion Corp Earnings Call
Aug 7, 2014
Q2 2014 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -5338.74% -1650.27%
Operating margin -5130.36% -3082.30%
EBITD margin - -3014.45%
Return on average assets -39.87% -23.23%
Return on average equity -62.31% -59.11%
Employees 13 -
CDP Score - -

Address

Suite 100, 997 Lenox Drive
LAWRENCEVILLE, NJ 08648
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized heat at mild hyperthermia temperatures releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. In June 2014, it acquired all of the assets of EGEN Inc.

Officers and directors

Max E. Link Ph.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
Michael H. Tardugno President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President - Corporate Strategy and Investor Relations
Age: 57
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Vice President, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 63
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 67
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters